pranlukast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
leukotriene receptor antagonists 2237 103177-37-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ONO 1078
  • pranlukast
  • onon
  • azlaire
  • pranlukast hydrate
  • ONO-1078
SRS-A antagonist; leukotriene D4 receptor antagonist
  • Molecular weight: 481.51
  • Formula: C27H23N5O4
  • CLOGP: 5.07
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 119.09
  • ALOGS: -5.20
  • ROTB: 9

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 15, 2007 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 35.76 32.80 19 552 127542 63360909

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilic granulomatosis with polyangiitis 35.60 33.09 8 603 1979 34954341
Hepatic function abnormal 33.40 33.09 16 595 44347 34911973

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 55.05 26 26 1302 73081 79669979
Asthma 30.56 26 22 1306 135073 79607987
Upper respiratory tract inflammation 30.33 26 8 1320 4027 79739033
Pyrexia 28.91 26 45 1283 678664 79064396
Concomitant disease aggravated 28.46 26 10 1318 13157 79729903
Eosinophilic granulomatosis with polyangiitis 26.28 26 7 1321 3653 79739407

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DC02 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Leukotriene receptor antagonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D006727 Hormone Antagonists
MeSH PA D020024 Leukotriene Antagonists
MeSH PA D019141 Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Asthma indication 195967001 DOID:2841




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.55 acidic
pKa2 10.08 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cysteinyl leukotriene receptor 1 GPCR ANTAGONIST IC50 10 IUPHAR SCIENTIFIC LITERATURE
Cysteinyl leukotriene receptor 2 GPCR ANTAGONIST IC50 5.44 IUPHAR
Bile acid receptor Nuclear hormone receptor EC50 4.82 CHEMBL
Uracil nucleotide/cysteinyl leukotriene receptor GPCR Ki 5.39 CHEMBL
Cysteinyl leukotriene receptor 1 GPCR Ki 9.10 CHEMBL
Replicase polyprotein 1ab Unclassified Kd 4.85 CHEMBL
Cruzipain Enzyme IC50 5.15 CHEMBL

External reference:

IDSource
D02732 KEGG_DRUG
C0526058 UMLSCUI
CHEBI:94810 CHEBI
KNT PDB_CHEM_ID
CHEMBL21333 ChEMBL_ID
CHEMBL11350 ChEMBL_ID
DB01411 DRUGBANK_ID
C047681 MESH_SUPPLEMENTAL_RECORD_UI
3634 IUPHAR_LIGAND_ID
6943 INN_ID
TB8Z891092 UNII
4887 PUBCHEM_CID
713438006 SNOMEDCT_US

Pharmaceutical products:

None